Alcon Inc. · NYSE (us_market)
Healthcare · Medical Instruments & Supplies · Switzerland
Alcon Inc. researches, develops, manufactures, distributes, and sells eye care products worldwide. The company operates through two segments, Surgical and Vision Care. It offers equipment, instrumentation and diagnostics, intraocular lenses (IOLs), and other implantables; and consumables, including viscoelastics, surgical solutions, incisional instruments, surgical custom packs, and other products for surgical procedures. The company's cataract products include Unity CS, LenSx laser system, Verion reference unit and Verion digital marker, ARGOS biometer, SMARTCATARACT health platform, NGENUITY 3D visualization system, LuxOR surgical ophthalmic microscope, and ORA system for intra-operative measurements; ADI cloud-based platform; and implantable products, including monofocal, Toric, and Presbyopia-Correcting IOLs, as well as delivery systems, such as AutonoMe and UltraSert. In addition, it provides Custom Pak surgical procedure packs vitreoretinal products comprising constellation vision systems, procedure packs, lasers and hand-held microsurgical instruments, Grieshaber, MIVS instruments; scissors, forceps and micro-instruments, medical grade vitreous tamponades, and Hypervit probes; and refractive surgery products, including WaveLight and Contoura Vision used for LASIK refractive procedure. Further, the company offers daily disposable, reusable, and color-enhancing contact lenses; ocular health products, such as dry eye, ocular allergies, glaucoma, and contact lens care, as well as ocular vitamins and redness relievers. The company was formerly known as Alcon Universal S.A. and changed its name to Alcon Inc. in December 2001. Alcon Inc. was founded in 1945 and is headquartered in Geneva, Switzerland.
| Event Period | Drawdown | Buy Point (Bottom) | Sell Point (Peak) | ticker.setupCols.buyScore | ticker.setupCols.sellScore | Max Return | Algo Return |
|---|---|---|---|---|---|---|---|
DROP2024-09-12$100.76 RISE2025-01-14$82.73 PEAK2025-03-27$96.80 196d | -17.9% 124d | Missed | Missed | — | — | +17.0% 72d | Missed |
DROP2023-08-29$85.20 RISE2023-11-16$69.57 PEAK2024-01-10$80.15 134d | -18.3% 79d | Missed | Missed | — | — | +15.2% 55d | Missed |
DROP2023-02-02$77.23 RISE2023-03-10$64.46 PEAK2023-05-19$81.79 106d | -16.5% 36d | Missed | Missed | — | — | +26.9% 70d | Missed |
DROP2022-07-29$78.09 RISE2022-11-03$56.51 PEAK2023-02-01$76.42 187d | -27.6% 97d | Missed | Missed | — | — | +35.2% 90d | Missed |
DROP2022-03-29$81.55 RISE2022-06-16$65.07 PEAK2022-07-29$78.09 122d | -20.2% 79d | Missed | Missed | — | — | +20.0% 43d | Missed |
DROP2021-12-29$88.50 RISE2022-05-09$64.25 PEAK2022-07-29$78.09 212d | -27.4% 131d | Missed | Missed | — | — | +21.5% 81d | Missed |
DROP2020-02-20$63.46 RISE2020-03-23$39.86 PEAK2020-06-03$64.16 104d | -37.2% 32d | Missed | Missed | — | — | +61.0% 72d | Missed |
Alcon's launch of Tryptyr and the unique mechanism and rapid tear production differentiate it in the mature dry eye disease market. See why ALC stock is a buy.
Alcon's Surgical and Vision Care units returned to 6% growth in Q1 2026, but tariffs, macro pressure and fierce competition still loom.
Recent share performance and business snapshot Alcon (SWX:ALC) has drawn attention after a period where the stock is down about 10% over the past month and about 17% over the past 3 months, while the company’s eye care business generated CHF 10,634.0 million in revenue and net income of CHF 819.0 million. See our latest analysis for Alcon. Looking beyond the recent pullback, Alcon’s share price return is down over the year and over multi year periods, while the latest short term recovery...
If you are wondering whether Alcon stock offers fair value around its recent price, or if the risks are starting to outweigh the potential, this article walks through the key signals to help you answer that for yourself. Over shorter periods the stock has been mixed, up 3.6% over the last week, but down 10.2% over the last month, 16.1% year to date, and 26.1% over the past year, which may have shifted how investors are thinking about both risk and opportunity. Recent coverage has focused on...
STERIS' Healthcare and AST segments post solid gains and milestones, but FX volatility, tariffs and global macro pressures threaten earnings variability.
Investing.com -- After one of the most contentious proxy battles in recent medical-device history, STAAR Surgical Company (NASDAQ:STAA) is beginning to prove that its standalone strategy can work. Last week, the Lake Forest-based leader in lens-based refractive surgery reported first-quarter financial results that came in well ahead of Wall Street expectations. The corporate milestone signals a strong operational turnaround just months after shareholders blocked a proposed acquisition by industr
National Vision beats EPS and revenue estimates as comps rise 4.5% and operating margin jumps 320 bps; 2026 guidance reiterated.
We recently compiled a list of the 8 Most Oversold Large Cap Stocks to Buy. Alcon Inc. (NYSE:ALC) is one of the most oversold stocks on this list. TheFly reported on May 8 that ALC saw its valuation outlook revised as Barclays reduced the price target to $78 from $90 while reiterating an Equal Weight rating […]
Prestige Consumer misses Q4 EPS and revenue estimates as Clear Eyes supply limits and Middle East shipping disruptions pressure sales and margins.
Alcidion Group’s fair value estimate is set at A$0.14 and remains unchanged in the latest update, even as underlying model inputs have been fine tuned. That stability lines up with recent sector research, where analysts often adjust discount rates and growth assumptions while keeping a steady view on valuation when product roadmaps, guidance and cash generation frameworks look consistent. Read on to see what is driving this refreshed narrative and how you can track the key signposts from...
STERIS posts Q4 adjusted EPS of $2.83 and revenues of $1.59 billion, both slight misses; shares dip after hours despite broad growth and FY27 guidance.
Weak earnings, soft guidance and analyst target cuts triggered sharp selloffs across healthcare, software, networking and industrial stocks last week, led by Zoetis, Insmed and HubSpot.
Barclays analyst Matt Miksic maintains Alcon (NYSE:ALC) with a Equal-Weight and lowers the price target from $90 to $78.
Wells Fargo analyst Larry Biegelsen maintains Alcon (NYSE:ALC) with a Overweight and lowers the price target from $97 to $86.
Mizuho analyst Anthony Petrone maintains Alcon (NYSE:ALC) with a Outperform and lowers the price target from $95 to $85.
Alcon Inc. (ALC) Q1 2026 Earnings Call May 6, 2026 8:00 AM EDTCompany ParticipantsDaniel Cravens - Vice President of Investor RelationsDavid Endicott - CEO...
Baird analyst Jeff Johnson maintains Alcon (NYSE:ALC) with a Outperform and lowers the price target from $98 to $90.
BTIG analyst Ryan Zimmerman maintains Alcon (NYSE:ALC) with a Buy and lowers the price target from $87 to $82.
Needham analyst David Saxon reiterates Alcon (NYSE:ALC) with a Buy and maintains $100 price target.
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| ALC | -10.53% | -21.72% | -15.89% | -22.86% |
| XLV | +2.97% | -5.72% | -3.44% | +12.69% |
| Alpha (stock − sector) | -13.50% | -16.00% | -12.44% | -35.55% |
| Fund | Style | Shares | Value | % of Port | Change vs. last quarter | Period |
|---|---|---|---|---|---|---|
| FidelityFMR | fundamental | 12.43M | $938.26M | 0.05% | Added+15.5% | 2026-03-31 |
| Citadel | multi-strat | 1.17M | $87.98M | 0.11% | Trimmed-34.3% | 2026-03-31 |
| DEShaw | quant | 1.16M | $87.45M | 0.05% | Added+7.7% | 2026-03-31 |
| TwoSigma | quant | 585.6K | $44.12M | 0.04% | Added+17.7% | 2026-03-31 |
| Wellington | fundamental | 100.9K | $7.44M | 0.00% | Trimmed-18.1% | 2026-03-31 |
| Bridgewater | macro | 28.9K | $2.18M | 0.01% | New | 2026-03-31 |
| StateStreet | passive | 6.1K | $461.37K | 0.00% | Unchanged | 2026-03-31 |
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-08-10upcoming | 0.75 | — | — |
| 2026-05-05 | 0.82 | 0.85 | +4.06% |
| 2026-02-24 | 0.79 | 0.78 | -1.32% |
| 2025-11-11 | 0.51 | 0.48 | -6.01% |
| 2025-08-19 | 0.71 | 0.76 | +6.75% |
| 2025-05-13 | 0.76 | 0.73 | -4.27% |
| 2025-02-25 | 0.72 | 0.72 | +0.57% |
| 2024-11-12 | 0.46 | 0.53 | +14.60% |
| 2024-08-20 | 0.39 | 0.45 | +15.75% |
| 2024-05-13 | 0.73 | 0.78 | +7.01% |
| 2024-02-27 | 0.68 | 0.70 | +3.54% |
| 2023-11-14 | 0.30 | 0.41 | +37.64% |
| 2023-08-15 | 0.30 | 0.34 | +14.64% |
| 2023-05-09 | 0.28 | 0.35 | +26.82% |
| 2023-02-27 | 0.42 | 0.42 | -1.10% |
| 2022-11-15 | 0.48 | 0.50 | +3.56% |